Cargando…

Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer

The enzyme human steroid 5-α reductase type II (SRD5A2) and androgen receptor (AR) are critical mediators of androgen action, suggesting a potential role in hormonally related cancers. The SRD5A2 gene harbours two frequent polymorphic sites, one in the coding region, at codon 89 of exon 1, where val...

Descripción completa

Detalles Bibliográficos
Autores principales: Scorilas, A, Bharaj, B, Giai, M, Diamandis, E P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363825/
https://www.ncbi.nlm.nih.gov/pubmed/11259089
http://dx.doi.org/10.1054/bjoc.2000.1681
_version_ 1782153801061367808
author Scorilas, A
Bharaj, B
Giai, M
Diamandis, E P
author_facet Scorilas, A
Bharaj, B
Giai, M
Diamandis, E P
author_sort Scorilas, A
collection PubMed
description The enzyme human steroid 5-α reductase type II (SRD5A2) and androgen receptor (AR) are critical mediators of androgen action, suggesting a potential role in hormonally related cancers. The SRD5A2 gene harbours two frequent polymorphic sites, one in the coding region, at codon 89 of exon 1, where valine is substituted by leucine (V89L) and the other in the 3′ untranslated region (3′ UTR) where a variable number of dinucleotide TA repeat lengths exists. The V89L polymorphism is known to alter the activity of this enzyme. In the present study we examined 144 sporadic breast tumours from Italian patients for the V89L and TA polymorphisms by sequence and fragment analysis, respectively. Tumour extract prostate specific antigen (PSA) concentration as well as a number of well-established clinical and pathological parameters were evaluated. The results show that 53% of the tumours were homozygous for VV alleles, 37% were heterozygous for VL alleles and 10% were homozygous for LL alleles. TA(0) repeats were found in tumours with VV, LL and VL genotypes. TA(9) repeats were only found in VV homozygotes and were totally absent from either LL homozygotes or VL heterozygotes. PSA expression was significantly elevated in tumours with VV genotype. The presence of LL alleles in breast tumours is associated with earlier onset and shorter disease-free (RR = 2.65;P = 0.013) and overall survival (RR = 3.06;P = 0.014) rates. The VV genotype is associated with a more favourable prognosis. Our study suggests that the polymorphism in codon 89 of exon 1 of the human 5α-reductase gene is related with TA repeat genotypes, PSA expression and breast cancer prognosis. More specifically, we found that the LL genotype is also associated with earlier onset and more aggressive forms of breast cancer. Long-term-outcome studies are needed to investigate the relevance of this polymorphism to breast cancer susceptibility. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363825
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23638252009-09-10 Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer Scorilas, A Bharaj, B Giai, M Diamandis, E P Br J Cancer Regular Article The enzyme human steroid 5-α reductase type II (SRD5A2) and androgen receptor (AR) are critical mediators of androgen action, suggesting a potential role in hormonally related cancers. The SRD5A2 gene harbours two frequent polymorphic sites, one in the coding region, at codon 89 of exon 1, where valine is substituted by leucine (V89L) and the other in the 3′ untranslated region (3′ UTR) where a variable number of dinucleotide TA repeat lengths exists. The V89L polymorphism is known to alter the activity of this enzyme. In the present study we examined 144 sporadic breast tumours from Italian patients for the V89L and TA polymorphisms by sequence and fragment analysis, respectively. Tumour extract prostate specific antigen (PSA) concentration as well as a number of well-established clinical and pathological parameters were evaluated. The results show that 53% of the tumours were homozygous for VV alleles, 37% were heterozygous for VL alleles and 10% were homozygous for LL alleles. TA(0) repeats were found in tumours with VV, LL and VL genotypes. TA(9) repeats were only found in VV homozygotes and were totally absent from either LL homozygotes or VL heterozygotes. PSA expression was significantly elevated in tumours with VV genotype. The presence of LL alleles in breast tumours is associated with earlier onset and shorter disease-free (RR = 2.65;P = 0.013) and overall survival (RR = 3.06;P = 0.014) rates. The VV genotype is associated with a more favourable prognosis. Our study suggests that the polymorphism in codon 89 of exon 1 of the human 5α-reductase gene is related with TA repeat genotypes, PSA expression and breast cancer prognosis. More specifically, we found that the LL genotype is also associated with earlier onset and more aggressive forms of breast cancer. Long-term-outcome studies are needed to investigate the relevance of this polymorphism to breast cancer susceptibility. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-03 /pmc/articles/PMC2363825/ /pubmed/11259089 http://dx.doi.org/10.1054/bjoc.2000.1681 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Scorilas, A
Bharaj, B
Giai, M
Diamandis, E P
Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
title Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
title_full Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
title_fullStr Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
title_full_unstemmed Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
title_short Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
title_sort codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363825/
https://www.ncbi.nlm.nih.gov/pubmed/11259089
http://dx.doi.org/10.1054/bjoc.2000.1681
work_keys_str_mv AT scorilasa codon89polymorphisminthehuman5areductasegeneinprimarybreastcancer
AT bharajb codon89polymorphisminthehuman5areductasegeneinprimarybreastcancer
AT giaim codon89polymorphisminthehuman5areductasegeneinprimarybreastcancer
AT diamandisep codon89polymorphisminthehuman5areductasegeneinprimarybreastcancer